97 Individual Cognitive Trajectories Post-Radiotherapy for Brain Metastases REFERENCES 1. Gerstenecker A, Nabors LB, Meneses K, et al. Cognition in patients with newly diagnosed brain metastasis: Profiles and implications. J Neurooncol. 2014;120(1):179-185. doi:10.1007/s11060-014-1543-x 2. Achrol AS, Rennert RC, Anders C, et al. Brain metastases. Nat Rev Dis Primers. 2019;5(1). doi:10.1038/s41572-018-0055-y 3. Nieder C, Spanne O, Mehta MP, Grosu AL, Geinitz H. Presentation, patterns of care, and survival in patients with brain metastases: What has changed in the last 20 years? Cancer. 2011;117(11):2505-2512. doi:10.1002/cncr.25707 4. Lanier CM, Hughes R, Ahmed T, et al. Immunotherapy is associated with improved survival and decreased neurologic death after SRS for brain metastases from lung and melanoma primaries. Neurooncol Pract. 2019;6(5):402-409. doi:10.1093/ nop/npz004 5. Nayak L, Lee EQ, Wen PY. Epidemiology of brain metastases. Curr Oncol Rep. 2012;14(1):48-54. doi:10.1007/s11912-011-0203-y 6. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden, Eleanor T Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology: Cancer Clinical Trials. 1982;5(6):649656. 7. Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37(4):745-751. doi:10.1016/ S0360-3016(96)00619-0 8. Sperduto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment: An accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. Journal of Clinical Oncology. 2012;30(4):419-425. doi:10.1200/JCO.2011.38.0527 9. Sperduto PW, Chao ST, Sneed PK, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys. 2010;77(3):655-661. doi:10.1016/j.ijrobp.2009.08.025 10. Eichler AF, Loeffler JS. Multidisciplinary management of brain metastases. Oncologist. 2007;12(7):884-898. doi:10.1634/theoncologist.12-7-884 11. Van Grinsven EE, Nagtegaal SHJ, Verhoeff JJC, Van Zandvoort MJE. The Impact of Stereotactic or Whole Brain Radiotherapy on Neurocognitive Functioning in Adult Patients with Brain Metastases: A Systematic Review and Meta-Analysis. Oncol Res Treat. 2021;44(11):622-636. doi:10.1159/000518848 12. Mehta MP, Rodrigus P, Terhaard CHJ, et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. Journal of Clinical Oncology. 2003;21(13):2529-2536. doi:10.1200/JCO.2003.12.122 13. Chang EL, Wefel JS, Maor MH, et al. A pilot study of neurocognitive function in patients with one to three new brain metastases initially treated with stereotactic radiosurgery alone. Neurosurgery. 2007;60(2):277-283. doi:10.1227/01.NEU.0000249272.64439.B1 4
RkJQdWJsaXNoZXIy MTk4NDMw